Holds 5 active US DMFs for empagliflozin, filing since 2018. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for empagliflozin, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds one active US DMF for empagliflozin, filing since 2022. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Holds one active US DMF for empagliflozin, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds one active US DMF for empagliflozin, filing since 2018. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds 2 active US DMFs for empagliflozin, filing since 2017. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Holds one active US DMF for empagliflozin, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds 2 active US DMFs for empagliflozin, filing since 2018. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds 4 active US DMFs for empagliflozin, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 14 markets.
Holds one active US DMF for empagliflozin, filing since 2019. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Holds one active US DMF for empagliflozin, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 9 markets.
Holds one active US DMF for empagliflozin, filing since 2018. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 2 active US DMFs for empagliflozin, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 7 markets.
Holds 2 active US DMFs for empagliflozin, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one active US DMF for empagliflozin, filing since 2024. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Holds one active US DMF for empagliflozin, filing since 2023. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for empagliflozin, filing since 2025. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Empagliflozin manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free